Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes by Houghton D et al.
ARTICLE
Systematic review assessing the effectiveness of dietary intervention
on gut microbiota in adults with type 2 diabetes
David Houghton1 & Timothy Hardy1,2 & Christopher Stewart3 & Linda Errington4 & Christopher P. Day1,2 &
Michael I. Trenell1 & Leah Avery1
Received: 11 December 2017 /Accepted: 5 March 2018
# The Author(s) 2018
Abstract
Aims/hypothesis Despite improved understanding of the pathophysiology of type 2 diabetes mellitus, explanations for individual
variability in disease progression and response to treatment are incomplete. The gut microbiota has been linked to the patho-
physiology of type 2 diabetes mellitus and may account for this variability. We conducted a systematic review to assess the
effectiveness of dietary and physical activity/exercise interventions in modulating the gut microbiota and improving glucose
control in adults with type 2 diabetes mellitus.
Methods A systematic search was conducted to identify studies reporting on the effect of dietary and physical activity/exercise
interventions on the gut microbiota and glucose control in individuals with a confirmed diagnosis of type 2 diabetes mellitus.
Study characteristics, methodological quality and details relating to interventions were captured using a data-extraction form.
Meta-analyses were conducted where sufficient data were available, and other results were reported narratively.
Results Eight studies met the eligibility criteria of the systematic review. No studies were found that reported on the effects of
physical activity/exercise on the gut microbiota and glucose control. However, studies reporting on dietary interventions showed
that such interventions were associated with modifications to the composition and diversity of the gut microbiota. There was a
statistically significant improvement in HbA1c (standardised mean difference [SMD] −2.31 mmol/mol [95% CI −2.76, −1.85]
[0.21%; 95% CI −0.26, −0.16]; I2 = 0%, p < 0.01), but not in fasting blood glucose (SMD −0.25 mmol/l [95% CI −0.85, 0.35],
I2 = 87%, p > 0.05), fasting insulin (SMD −1.82 pmol/l [95% CI −7.23, 3.60], I2 = 54%, p > 0.05) or HOMA-IR (SMD −0.15
[95% CI −0.63, 0.32], I2 = 69%, p > 0.05) when comparing dietary interventions with comparator groups. There were no
significant changes in the relative abundance of bacteria in the genera Bifidobacterium (SMD 1.29% [95% CI −4.45, 7.03],
I2 = 33%, p > 0.05), Roseburia (SMD −0.85% [95% CI −2.91, 1.21], I2 = 79%, p > 0.05) or Lactobacillus (SMD 0.04% [95% CI
−0.01, 0.09], I2 = 0%, p > 0.05) when comparing dietary interventions with comparator groups. There were, however, other
significant changes in the gut microbiota, including changes at various taxonomic levels, including phylum, family, genus and
species, Firmicutes:Bacteroidetes ratios and changes in diversity matrices (α and β). Dietary intervention had minimal or no
effect on inflammation, short-chain fatty acids or anthropometrics.
Conclusions/interpretation Dietary intervention was found to modulate the gut microbiota and improve glucose control in
individuals with type 2 diabetes. Although the results of the included studies are encouraging, this review highlights the need
for further well-conducted interventional studies to inform the clinical use of dietary interventions targeting the gut microbiota.
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Introduction
The incidence of type 2 diabetes mellitus is steadily increasing
and the worldwide incidence is predicted to exceed 500 mil-
lion by 2030 [1]. Although pharmacotherapy offers a manage-
ment option for individuals with type 2 diabetes, lifestyle in-
terventions, including modifications to diet and physical
activity/exercise levels with weight loss of 5–10%, remain
the cornerstone of treatment [2]. Nonetheless, concerns re-
main relating to adherence, implementation, specificity and a
lack of long-term randomised trials in clinical practice, and
these hinder the clinical use of such interventions [3].
Furthermore, there is substantial inter-individual variability
in disease pathophysiology and response to treatments [4].
A potentially new therapeutic target receiving considerable
interest is the collection of microorganisms, specifically
bacteria that reside within the gastrointestinal tract, which
are termed the ‘gut microbiota’. Advances in molecular se-
quencing and computational methods have provided an un-
precedented understanding of how the gut microbiota func-
tions in a symbiotic nature with the host, contributing to nu-
trition, metabolism, immune response and intestinal architec-
ture [5, 6]. Alterations in the composition of the gut microbi-
ota, termed ‘dysbiosis’ [7], have been linked to conditions
including type 2 diabetes mellitus [8, 9] and metabolic disor-
ders [10, 11]. Although the exact mechanisms linking the gut
microbiota and type 2 diabetes mellitus remain unknown, dif-
ferences in the composition of the gut microbiota may con-
tribute to the variability observed among individuals with type
2 diabetes mellitus [12].
The gut microbiota influences energy harvest [12], blood
glucose [13] and the effectiveness of pharmacotherapy [14].
Furthermore, targeting the gut microbiota with lifestyle inter-
ventions has been shown to result in significant changes in
bacterial composition that are aligned with improvements in
glucose control [15–25]. However, studies to date have gen-
erally been in animal models or in individuals without a clin-
ical diagnosis of type 2 diabetes mellitus. Our aim was to
conduct a systematic review to identify studies of lifestyle
interventions (i.e. dietary and physical activity/exercise inter-
ventions) involving adults with type 2 diabetes mellitus, and
•
•
•
•
•
•
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to assess the effectiveness of these interventions on modulat-
ing the gut microbiota and improving glucose control.
Methods
This systematic review was conducted according to a pub-
lished protocol [26] and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines [27].
Eligibility criteria Included studies were RCTs or specific arms
of non-RCTs that reported on the effectiveness of dietary and
physical activity/exercise interventions on modulating the gut
microbiota and improving glucose control (i.e. HbA1c, fasting
blood glucose, 2 h frequently sampled [2 hfs] OGTT and/or
HOMA-IR or insulin). Participants of interest were adults with
type 2 diabetes. Studies reporting on lifestyle interventions in
adults with type 1 diabetes were excluded.
It was a requirement that the gut microbiota was measured
from stool samples using any form of sequencing technique
targeting the 16S ribosomal RNA gene. No standardised
criteria defining type 2 diabetes mellitus were specified be-
cause the methods for clinical diagnosis vary between studies.
However, individuals with type 2 diabetes mellitus had to be
clinically diagnosed with their diabetes controlled by diet, oral
medication and/or insulin.
Eligible lifestyle interventions included those that targeted
diet, physical activity/exercise, use of prebiotics, probiotics or
synbiotics, or a combination of these. Studies that included
pharmacotherapy, herbal remedies and surgery were excluded.
Studies where individuals were already receiving medication
as part of their standard care and with no increase in dose
during the study were eligible for inclusion.
The primary outcomes of interest were modulation of the
gut microbiota, including changes in the relative abundance of
bacteria and diversity changes (α and β), and glucose control.
The composition of the gut microbiota could also be reported
as a secondary outcome. Other secondary outcomes were
changes in weight and inflammatory markers (i.e. IL-6,
TNF-α, IL-1 receptor antagonist [IL-1RA], C-reactive protein
[CRP] and faecal lipocalin-2).
Search strategy MEDLINE, EMBASE, Scopus, Web of
Science and the Cochrane Library were searched using a com-
bination of MeSH headings and keywords to identify poten-
tially relevant literature (see electronic supplementary material
[ESM] Methods). Searches were completed up to 9 February
2017 and were limited to studies published in the English
language. Manual searching (i.e. reference lists and citation
searching) of studies fulfilling the eligibility criteria was also
conducted.
Selection of studies Two authors (D. Houghton and T. Hardy)
independently screened the titles and abstracts of all the stud-
ies generated by the search. Full-text articles retained from the
first stage were reassessed independently by the same two
authors and assessed by a third independent author (C.
Stewart) using a study-selection form. Any disagreements
were resolved via discussion with the review team.
Data extraction Details of the study population, interventions,
comparators and outcomes were captured using a data-
extraction form. Data were extracted from all included studies
independently by two members of the review team (D.
Houghton and T. Hardy). Where applicable, the corresponding
authors from the retained studies were contacted via email to
request additional information. The Cochrane Collaboration risk
of bias tool [28] was used to assess themethodological quality of
the included studies and the overall risk of bias (i.e. low, unclear
or high). All studies were independently assessed for methodo-
logical quality by two authors (D. Houghton and L. Avery).
Data synthesis Insufficient data were reported to enable over-
all effect-size estimates to be calculated using meta-analyses
for all outcomes of interest; therefore, the study authors were
contacted to request additional outcome data where applica-
ble. This enabled meta-analyses to be conducted for the com-
position of the gut microbiota (Bifidobacterium, Roseburia
and Lactobacillus) and for fasting blood glucose, HbA1c, in-
sulin and HOMA-IR levels. Results for other outcomes of
interest are presented narratively. Data are expressed as
standardised mean difference (SMD) (95% CI) between treat-
ment and control/comparator groups.
Results
The electronic search returned 2513 potentially relevant stud-
ies. An additional 121 studies were identified from the end
reference lists of the included studies and conference proceed-
ings. Following the removal of duplicates and elimination of
ineligible studies, eight studies were retained for review (Fig.
1). All eight studies reported on the effect of dietary interven-
tions (i.e. no studies were retrieved meeting the eligibility
criteria that reported on physical activity/exercise alone).
These studies were seven RCTs [29–35] and one single-
group study [36]. Four of the studies were conducted in
Europe (Denmark, Spain, Italy and the UK) and four in Asia
(India, Malaysia, Japan and the Republic of Korea). All eight
studies used dietary modulation alone (Table 1).
Characteristics of participants with type 2 diabetes The total
sample size across the included studies was 395, including at
least 225 men and 135 women; one study failed to report the
sex of participants (n = 35) [35]. Participants were aged 33–
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77 years (58 ± 4 years [mean ± SD]) with a BMI range of 25–
45 kg/m2. Six studies recruited only individuals diagnosed
with type 2 diabetes mellitus [29, 30, 32–35]. One study com-
pared participants with type 2 diabetes mellitus and control
participants at baseline, prior to the introduction of any inter-
vention, however, these 13 participants were not included in
the analyses reported here [32]. Two studies [31, 36] reported
on a sample including individuals with and without type 2
diabetes mellitus (Table 1). Only one study reported the eth-
nicity of participants and none of the included studies reported
the time since diagnosis of type 2 diabetes mellitus. Five stud-
ies reported treatment regimens: insulin injection (n = 11), in-
sulin secretagogue (n = 34), metformin (n = 52), sulfonylurea
(n = 12), α-glucosidase inhibitor (n = 41), sitagliptin (n = 7),
thiazolidinedione (n = 1), peroxisome proliferator-activated
receptor γ (PPAR-γ) antagonist (n = 15) or statins (n = 5)
[30, 31, 34]. One study recruited individuals who managed
their type 2 diabetes mellitus through diet only [29], and two
studies used eligibility criteria that restricted the use of insulin
but allowed hypoglycaemic drugs and dietary interventions,
but provided no specific details [32, 33]. Two studies [35, 36]
did not report any treatment regimens (Table 1).
Intervention characteristics The duration of interventions
ranged from 21 days to 6 months. All included studies
involved some form of dietary intervention, including dietary
manipulation and/or supplements. One RCT supplemented
participants with a synbiotic [35], one single-group study
instructed participants to follow a strict vegetarian diet [36],
one RCT [32] instructed participants to follow a strict Ma-Pi
diet [37] and a further RCT asked participants to follow a diet
recommended for type 2 diabetes mellitus incorporating an
increased intake of sardines [29]. The last two of these studies
included information on nutrient intake, althoughBalfegó et al
[29] did not provide any information on what constituted the
type 2 diabetic diet. Two RCTs provided participants with
probiotics [31, 33], but only one recorded nutrient intake
and provided guidelines on dietary intake based on type 2
diabetes mellitus guidelines [33]. One RCT provided a prebi-
otic, detailed in Vulevic et al [38], with no dietary advice, but
recorded nutrient intake [34]; and one RCT provided partici-
pants with a digestive supplement and recorded nutrient intake
at baseline [30].
All eight studies reported on glucose control, including
HbA1c, fasting blood glucose, 2 h
fs OGTT, HOMA-IR or in-
sulin, or a combination of these, and the gut microbiota (using
various techniques; ESM Table 1).
Methodological quality assessment All included studies were
assessed for methodological quality using the Cochrane
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Collaboration risk of bias tool (Table 2) [28]. Seven studies
explicitly reported their hypotheses, objectives, statistical test-
ing procedures and main findings. Four studies reported a
power calculation including details of whether sample size
was obtained [30, 31, 33, 34]. Only one study retained the
sample size at follow-up [31]. One study provided a power
calculation based on changes in TNF-α upon request [31].
However, it is unclear from the information reported in the
article whether this was the primary outcome, making it diffi-
cult to establish whether the sample size was adequate. All but
one study [35] reported attrition rates, and one study reported
using an intention-to-treat analysis [33].
Four studies provided enough information to confirm the
use of adequate sequence generation [29, 30, 33, 34], two
studies provided sufficient detail on the methods used to con-
ceal allocation sequences [30, 33] and three studies provided
explicit detail on blinding of the research team [30, 31, 33].
Seven studies provided detail on outcome assessors [29–34,
36] and five studies provided sufficient detail to establish the
likely absence of selective outcome reporting [29, 32–35].
Overall, seven of the studies were considered to be low risk
of bias [29–34, 36] and the risk of bias of one [35] was unclear
(Table 2).
Effects of lifestyle modulation on gut microbiota Additional
data on the gut microbiota were requested from all authors of
the included studies. Two studies comparing supplementation
with a prebiotic vs control for 12 weeks [34] and the Ma-Pi
diet vs a control diet for 21 days [32] provided sufficient data
for meta-analyses to be conducted. Changes in the relative
abundance of bacteria in the genera Bifidobacterium (SMD
1.29% [95% CI −4.45, 7.03], I2 = 33%), Roseburia (SMD
−0.85% [95% CI −2.91, 1.21], I2 = 79%) and Lactobacillus
(SMD 0.04% [95% CI −0.01, 0.09], I2 = 0%) (ESM Fig. 1)
were reported, however, these changes were not significantly
different when comparing dietary interventions with controls.
Candela et al [32] compared a fibre-rich macrobiotic diet
with a control diet. The authors reported a significant change
in weighted UniFrac following receipt of the intervention.
Levels of Faecalibacterium were significantly negatively cor-
related with fasting blood glucose; Akkermansia and
Bacteroides both showed a positive significant relationship
with LDL-cholesterol; and Ruminococcus was significantly
positively correlated with fasting blood glucose. Significant
increases in the relative abundance of Peptostreptococcaceae
and Leuconostocaceae were also reported, and both of these
genera were positively correlated with dietary components
(fermented products).
Balfegó et al [29] compared a type 2 diabetes diet, one
enriched with 100 g of sardines and one without. The authors
reported a decrease in Firmicutes and an increase in
Escherichia coli in both groups between baseline and study
completion. In the sardine enriched group there was also a
decrease in the Firmicutes:Bacteroidetes ratio and an increase
in Bacteroides-Prevotella when compared with baseline. Kim
et al [36] reported a significant increase in the relative abun-
dance of Bacteroidetes and a correlation between weighted and
unweighted UniFrac and a strict vegetarian diet. However,
these analyses involved the whole sample of participants, in-
cluding those without a confirmed diagnosis of type 2 diabetes.
Two RCTs [31, 33] supplemented participants with probiotics
and reported significant changes in bacterial composition:
Andreasen et al [31] reported a significant increase in the pres-
ence of Lactobacillus acidophilus from near non-detectable
levels to 6.4 colony-forming units; and similarly, Firouzi et al
[33] reported significant increases of 4.5- and twofold in
Bifidobacterium and Lactobacillus spp., respectively.
Pedersen et al [34] conducted an RCT in which participants
were supplemented with a prebiotic compared with placebo.
No between-group differences were shown; however, an in-
crease in α diversity was reported within the prebiotic group.
Furthermore, correlations between bowel permeability, meta-
bolic profile, inflammatory markers and bacteria were report-
ed (ESM Table 2). Sheth et al [35] supplemented participants
with a synbiotic (two species of Lactobacillus and
Bifidobacterium each, one species of Streptococcus and yeast,
and 300 mg oligosaccharide), although the dietary intake pro-
vided alongside the supplements was unclear. Increases in
both Lactobacillus and Bifidobacteriumwere reported follow-
ing the intervention. Sasaki et al [30] reported significant
changes in the Firmicutes:Bacteroidetes ratio between base-
line and 12 weeks following supplementation with 300 and
900 mg/day of transglucosidase.
Effects of dietary intervention modulation on glucose control
Four studies comparing dietary interventions including prebi-
otics, probiotics and Ma-Pi diet vs controlled diets for a dura-
tion of between 21 to 84 days reported or provided sufficient
data to enable meta-analyses of fasting blood glucose, HbA1c,
fasting insulin and HOMA-IR (ESM Fig. 2) [30, 32–34].
Reductions were shown in all glucose control variables.
HbA1c was significantly reduced (standardised mean differ-
ence [SMD] −2.31 mmol/mol [95% CI −2.76, −1.85] [0.21%;
95% CI −0.26, −0.16]; I2 = 0%, p < 0.01), however, fasting
blood glucose (SMD −0.25 mmol/l [95% CI −0.85, 0.35],
I2 = 87%, p > 0.05), fasting insulin (SMD −1.82 pmol/l [95%
CI −7.23, 3.60], I2 = 54%, p > 0.05) and HOMA-IR (SMD
−0.15 [95% CI −0.63, 0.32], I2 = 69%, p > 0.05) were not
significantly reduced when comparing dietary interventions
with comparator groups.
All eight studies reported on glucose control; however,
only four provided sufficient data to calculate overall effect
sizes [30, 32–34] (ESM Fig. 2). Kim et al [36] and Sasaki et al
[30] reported positive changes in fasting blood glucose, 2 hfs
OGTT, fasting insulin and HbA1c, although these were not
statistically significant. Andreasen et al [31] reported baseline
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fasting blood glucose, HbA1c, 2 h
fs OGTTand HOMA-IR, but
did not report data for these variables at the 4 week follow-up
point. A significant between-group improvement in insulin
sensitivity was reported, but post-hoc t tests revealed no sig-
nificant within-group changes. Unfortunately, analyses were
not reported for participants with type 2 diabetes mellitus only,
making it difficult to extrapolate the effects of the intervention.
Two RCTs showed significant improvements in glucose
control [29, 32]. Candela et al [32] reported reductions in
fasting blood glucose (−2.3 vs −1.9 mmol/l), postprandial
blood glucose (−4.0 vs −4.3 mmol/l), HbA1c (−5.5 vs
−2.2 mmol/mol [−0.5% vs −0.2%] and HOMA-IR (−1.9 vs
−1.5). Balfegó et al [29] reported significant reductions in
fasting insulin (−35% vs −23%) and HOMA-IR (−49% vs
−22%) for treatment and comparator groups, respectively.
Three RCTs supplemented participants with a prebiotic, pro-
biotic or synbiotic. Firouzi et al [33] reported significant re-
ductions in insulin at 6 and 12 weeks (−16 and −20 pmol/l,
respectively) and HbA1c at 12 weeks (−1.1 mmol/mol
[−0.1%]) between the probiotic and control group. Sheth
et al [35] reported reductions in fasting blood glucose, post-
prandial blood glucose and HbA1c; however, it is unclear from
the reported findings whether differences between groups
were assessed, as data were not provided. Pedersen et al [34]
reported no statistical improvements in glucose control fol-
lowing supplementation with prebiotics.
Effects of dietary intervention modulation on inflammation
Four studies reported no significant differences in the inflam-
matory markers TNF-α, IL-6, IL-1RA or CRP between
groups [29, 31, 33, 34]. Kim et al [36] reported significant
reductions in faecal lipocalin 2; however, these analyses in-
cluded participants without type 2 diabetes mellitus, making it
difficult to extrapolate results for the subgroup of participants
with type 2 diabetes. One RCT reported significant reductions
in TNF-α, IL-6 and CRP following 21 days consuming the
Ma-Pi 2 diet [32].
Effects of dietary intervention on short-chain fatty acids Kim
et al [36] reported a significant increase in butyrate and a
reduction in total short-chain fatty acids (SCFAs), acetate,
propionate and butyrate concentrations. However, these anal-
yses were conducted on all individuals recruited, including
those without a confirmed diagnosis of type 2 diabetes.
Sheth et al [35] also reported increased concentrations in bu-
tyrate and propionate, although it is unclear what statistical
analyses were conducted.
Effects of dietary intervention on anthropometrics Seven
studies reported BMI at baseline [29–34, 36] and six of these
studies reported BMI postintervention [29, 30, 32–34, 36].
Five studies reported no significant changes in anthropomet-
rics, including weight, BMI and hip and waist circumferences
[29, 30, 32–34]. Kim et al [36] provided BMI data upon re-
quest showing a postintervention reduction; however, it is
unclear from the published article or the additional informa-
tion provided whether this was statistically significant.
Changes in nutrition Four studies recorded nutritional intake
at baseline and the postintervention follow-up, including en-
ergy intake and the consumption of fat, protein, carbohydrates
and fibre. Although Candela et al [32] reported dietary intake,
no statistical analyses were reported. Firouzi et al [33] report-
ed a statistically significant 9% reduction in fat intake and
Balfegó et al [29] reported an 11% reduction in energy intake.
Pedersen et al [34] reported a statistically significant 1.1%
increase in protein intake in the control group compared with
the prebiotic group.
Discussion
This systematic review aimed to assess the effectiveness of
lifestyle interventions targeting diet and/or physical activity/
exercise for modulating the gut microbiota and improving
glucose control in adults with type 2 diabetes. Previous re-
views have reported the effects of lifestyle interventions on
their ability to improve glucose control in adults with type 2
diabetes [39–42]. To the best of our knowledge, however,
there have been no published reviews on the effectiveness of
lifestyle interventions targeting the gut microbiota in combi-
nation with changes in glucose control in adults with type 2
diabetes. Although no eligible studies were retrieved reporting
on the effect of physical activity/exercise on the gut microbi-
ota and metabolic health, the evidence generated by this re-
view demonstrates that dietary interventions can modulate the
gut microbiota while improving glucose control.
Advances in microbiome research have revealed the impor-
tance of individual variability in the composition of the gut
microbiota in supporting health and contributing to disease
[6]. One key environmental factor that shapes the gut microbi-
ota composition is diet, influencing gut transit time, pH and
macronutrient ingestion [43]. All of the studies reviewed here
reported significant changes in the gut microbiota composition
following dietary intervention [29–36], supporting the findings
of previously published studies in children and adults [44, 45].
The current review found that changes in metabolic health
were closely related to significant changes in gut microbiota
composition, including changes at various taxa levels (e.g.
phylum, family, genus, species and Firmicutes:Bacteroidetes
ratio).
Meta-analysis showed no significant changes in the relative
abundance of three potentially healthy-gut-promoting bacteria
at the genus level: Bifidobacterium, Roseburia and
Lactobacillus. A potential explanation is the small sample size
of the intervention groups (n = 21 and n = 14) and short
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duration (3 and 12 weeks) of the included trials, the content/
nature of the dietary intervention (Ma-Pi 2 diet and prebiotic)
and the small number of studies included in the meta-analysis
(n = 2) [32, 34], respectively. In contrast to the outcome of the
meta-analysis, all of the studies reviewed did report statistical-
ly significant changes in different gut microbiota variables.
For example, significant changes were reported in the relative
abundances at the phylum (Firmicutes, Bacteroidetes), family
(Peptostreptococcaceae and Leuconostocaceae) genus
(Prevotella, Bifidobacterium and Lactobacillus) and species
(L. acidophilus) level, and in α (Shannon and inverse
Simpson) andβ (weighted and unweighted UniFrac) diversity
matrices. Furthermore, significant correlations were reported
between various bacteria and metabolic variables such as
fasting blood glucose and LDL-cholesterol. These data pro-
vide support for the ability of dietary intervention to modulate
the gut microbiota; however, the gut microbiota field is still
relatively young and our understanding of what these changes
mean is limited. This issue is further complicated by observa-
tions being made at the bacterial level and not taking into
account functionality, as reported in this review.
A potential issue identified was variability among partici-
pants within the gut microbiota studies reviewed.
Furthermore, to observe a genuine effect of an intervention
in this field requires an adequate sample size to account for
the substantial variability both within and between studies
reporting on the gut microbiota, and strictly controlled inter-
vention studies that adopt consistent methods and interven-
tions to allow comparisons to be made. The heterogeneity of
the results highlighted could be explained by these issues.
The mechanisms linking changes in bacterial composition
to metabolic dysfunction have not been confirmed. Potential
mechanisms include: (1) altered levels of glucagon-like pep-
tide-1 and -2 [15]; (2) increased lipopolysaccharides; (3) in-
flammation [18]; (4) reduced SCFAs and appetite [46]; and (5)
increased energy extraction from digesta [12]. Although not
exhaustive, this list highlights the potential contributions of
the gut microbiota to type 2 diabetes; however, the pathophys-
iological processes remain unknown. This is primarily be-
cause the gut microbiome field is still in its infancy, although
we will undoubtedly learn more about the contribution of the
gut microbiota towards type 2 diabetes mellitus in this grow-
ing field of research. However, this review does support the
importance of dietary change and its ability to modulate the
gut microbiota in an attempt to maintain gut homeostasis and
improve glucose control, as previously shown [13]. Targeting
the gut microbiota and/or using the information generated
from gut microbiome studies could offer an alternative thera-
peutic approach that takes into account the substantial vari-
ability observed among individuals with type 2 diabetes
mellitus.
In addition to dietary change, previous research has shown
that exercise impacts positively on health outcomes, including
immune function, and has anti-inflammatory effects [22, 47].
However, the search conducted for this systematic review did
not identify any studies reporting on the effects of physical
activity/exercise on the gut microbiota and glucose control
that met the eligibility criteria. This highlights a gap in the
evidence base and thus a need for well-conducted studies in
this area. At the time of the search, the studies by Clarke et al
[22] and Shukla et al [48] were the only ones to have investi-
gated the effects of exercise on the gut microbiota in humans,
reporting positive and negative outcomes, respectively,
questioning its use in clinical practice.
A body of evidence from clinical studies [49] and preclin-
ical models [50, 51] demonstrates that exercise reduces in-
flammation, upregulates glucagon-like peptide-1 secretion
[52] and modulates the gut microbiota. Furthermore, interven-
tions targeting physical activity/exercise have also been
shown to improve glucose control [41], body composition
and liver fat in humans with fatty liver disease [53] and type
2 diabetes mellitus [54], irrespective of weight loss. The exact
mechanisms behind how physical activity/exercise modulates
the gut microbiota and risk factors for type 2 diabetes mellitus
in combination remain unknown. Potential mechanisms in-
clude altered SCFAs, cholesterol metabolism, substrate for
bacterial growth and gastrointestinal tract transit time; howev-
er, this review highlights a lack of research and therefore un-
derstanding in this area, which hinders its clinical use at
present.
This systematic review has provided evidence to demon-
strate that diet has an important role in modulating the gut
microbiota, which has been linked with disease pathophys-
iology. This has important clinical implications and further
supports the importance of targeting the gut microbiota in
lifestyle interventions as a therapeutic pathway in clinical
practice.
Strengths of this systematic review include the transfer-
ability of the findings to clinical environments (the includ-
ed studies were conducted in primary- and secondary-care
settings) and the clinical group studied (i.e. people with
type 2 diabetes mellitus), demonstrating potential clinical
use. Despite the small numbers of studies reviewed (n = 8),
encouragingly all scored high in terms of methodological
quality, suggesting that the conclusions can be considered
reliable. However, it should be noted that the studies in-
cluded were small in terms of sample size (n = 395) and
were of short duration, and samples consisted of a dispro-
portionately small number of women, which could limit
generalisability. Although all of the studies included incor-
porated dietary modification, including specific diets and/
or some form of supplementation, these were heteroge-
neous in nature (i.e. the diets used differed among studies
in terms of the dietary approach and nutritional content).
Dietary supplementation was commonly used, and generic
probiotics, prebiotics and synbiotics were provided.
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Finally, various methods of sequencing 16S ribosomal
RNA (culture methods vs next-generation sequencing)
and reporting results meant that levels of heterogeneity
arising from the meta-analyses conducted were often high,
and make an overall understanding difficult.
Conclusion/future directions Lifestyle intervention holds po-
tential for improving the gut microbiota and glucose control.
To truly use the potential of the gut microbiota and its impli-
cations for disease pathophysiology and health, future studies
should consider using an appropriate intervention duration
and sample size, and conducting long-term follow-up to assess
whether changes in the gut microbiota and glucose control are
maintained. Lifestyle behaviour change through a combina-
tion of diet and/or physical activity/exercise has been shown
to have a significant beneficial impact upon glucose control
[55]. However, the role that the gut microbiota plays in this
process remains unclear. Another unanswered question is why
some individuals respond to interventions more profoundly
than others. To date, studies have focused predominantly on
preclinical models, limiting their transferability into humans
for use as therapeutic interventions. This review highlights the
need for further well-conducted human intervention studies.
As the pathology of type 2 diabetes mellitus advances and our
understanding of the gut microbiota increases, there is signif-
icant potential to determine the importance of specific bacteria
and their function in a given bacterial community. This will, in
turn, lay the foundation for translating preclinical data into
clinical practice by integrating multiple techniques and the
characteristics of individuals into a systems biology approach
to provide personalised lifestyle interventions.
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